A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

clinical trial

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00055471

P6099clinical trial phasephase II clinical trialQ42824440
P17countryUnited States of AmericaQ30
P582end time2005-10-01
P921main subjectmetastatic prostate carcinomaQ55779807
P2899minimum age18
P1132number of participants22
P580start time2003-06-01
P8363study typeinterventional studyQ78089383

Search more.